IL36G and neoplasm: demonstrated that CAR-T-mediated secretion of IL-36γ can also contribute to the mounting of collateral antitumor effects through the activation of APCs and T cells nearly aborting the outgrowth of tumor cells with the loss of CAR-T target antigen (161).